The Map to Pain-Free Injectables and Precision Medicine
What if you never needed to get a shot ever again? In a new study published in Advanced Materials, Dr. Netra Unni Rajesh and colleagues from the DeSimone Lab at Stanford U. have reimagined the humble microneedle array patch – tiny skin-perforating devices that have long promised to make needle-based medicine more accessible and less painful – by harnessing the transformative power of advanced 3D printing. This work isn’t about turning these patches into long-term wearables; it’s about creating single-use, high-precision delivery devices that expand what’s possible in the clinic and beyond.
Traditional microneedle patches have been constrained by the rigid shapes and fragile materials of earlier generations. Silicon-based arrays, labor-intensive photolithography, and the challenge of scaling these devices for real-world use have held back widespread adoption. At a TED Talk in 2015, Prof. DeSimone joked, “3D printing is actually a misnomer; it’s actually 2D printing over and over again… There are mushrooms that grow faster than 3D printed parts.” Rather than printing layer by layer, the DeSimone Lab developed continuous liquid interface production (CLIP) (Tumbleston et al., 2015), which leverages light and oxygen to grow parts continuously. Prof. DeSimone founded Carbon to scale CLIP manufacturing capabilities, and this technology has already been used to precision-engineer everything from sports equipment to dental devices.
An array of lattice designs
The team at Stanford used CLIP to craft a library of 3D-printed lattice microneedle array patches (L-MAPs) that incorporate hollow cells within each needle structure, a design previously impossible with traditional printing methods. These lattice voids aren’t just structural quirks; they create an unprecedented ability to load both solid and liquid cargo onto a single patch – making it possible, for instance, to co-deliver a thermostable solid antigen with a liquid mRNA-based adjuvant. Beyond rethinking how needles are shaped, this approach redefines what a delivery device can be. Traditional patches relied on uniform, solid projections that could only carry a small amount of one type of drug. In contrast, these new latticed designs allow for precise spatial patterning of multiple cargo types, essentially transforming each patch into a modular micro-factory. It’s a concept that collapses the boundary between drug and device, and hints at a future where a single patch could contain different drug types for simultaneous or staggered release, tailored to complex treatment regimens.
The DeSimone team didn’t just design these lattices; they rigorously validated them. Mechanical testing confirmed that the L-MAPs buckle safely – rather than fracturing – under pressure, minimizing the risk of fragments being left behind in the skin. In skin models, these lattices delivered twice the cargo of conventional patches, including proteins and lipid nanoparticle-encapsulated mRNA – the very tools that have driven the latest waves of vaccine development.
Preparing for the medical market
And while Carbon already produces a broad range of products, the announcement about PinPrint is hot off the presses as a spinout poised to translate these microneedle breakthroughs directly into therapeutic applications. PinPrint’s mission isn’t just about proving that these patches work in a lab – it’s about turning them into viable clinical products, from self-administered vaccines to treatments for hard-to-reach disease targets. These “hard-to-reach” diseases are not only difficult to treat due to anatomy but also have challenges from biochemistry. Many emerging therapies require delivery to immuno-privileged tissues or depend on delicate molecules that degrade quickly in circulation. Delivering these through a transdermal route – without needing refrigeration, injection equipment, or trained personnel – could rewrite access equations for conditions like HPV, HIV, and even neurodegenerative diseases via peripheral biomarkers.
The engineering complexity behind these lattices also offers another advantage: the ability to create patches with multiple needle designs on a single patch. In their work, the team developed hybrid patches that integrate different needle geometries within one device, allowing them to deliver drugs with distinct release profiles simultaneously. This kind of multiplexed delivery system has the potential to revolutionize how we think about combination therapies or drug cocktails – no more separate injections or staggered pills, but a single patch with a choreography of precise micro-deliveries.
The translational challenge is clear: how do we scale these devices beyond research use, ensuring safety, regulatory compliance, and economic feasibility? But with PinPrint’s focus on therapeutic applications and Carbon’s already-proven manufacturing infrastructure – this vision is closer to clinical reality than ever.
Precision plus adaptability
Equally striking is how these single-use microneedle arrays address a persistent challenge in transdermal drug delivery: the mismatch between the body’s protective skin layers and the need to deliver large or delicate therapeutic molecules. The skin’s outer layer, the stratum corneum, is less than 20 microns thick, but it’s a formidable barrier to most drugs. By puncturing just past this layer, without hitting pain receptors or blood vessels, L-MAPs navigate this barrier with minimal discomfort and maximum precision.
This kind of precision requires both mechanical performance and robustness. By ensuring that needles buckle rather than snap, the team minimized the risk of inflammation or infection from residual fragments – an essential safety consideration. In the broader context of patient acceptance, these features could mean the difference between adoption and rejection of this technology in real-world settings.
Importantly, this precision is coupled with adaptability. The researchers used in-silico modeling to tweak every variable: the width of each needle’s strut, the angle of tapering, and the spacing of the lattice cells. This means that each patch can be tailored for different therapeutic applications, from rapid-release vaccines to slow-release cancer immunotherapies. Such design freedom is almost impossible to achieve with older photolithography-based or mold-cast microneedles.
Co-design of delivery and medication
What makes CLIP so uniquely suited to this task isn’t just its speed – it’s the ability to print gradients and curvature with microscopic resolution. Imagine a future where every patient receives a patch printed specifically for their physiology, their medication, and their lifestyle. The shift from mass-manufactured medicine to individualized pharmacotherapy may be powered not by a new molecule, but by a new manufacturing paradigm.
This work exemplifies a broader shift in bioelectronics: rethinking both the materials we use and the architectures we build to interface with the human body. If the 20th century of medicine was about synthesizing new molecules, the 21st may be about co-development of medicine and smarter, more adaptable ways to deliver them. In doing so, the lines between molecular design and biological function begin to blur. A patch is no longer just a delivery tool – it’s a digitally fabricated interface with the body’s own networks. As additive manufacturing increasingly intersects with synthetic biology, we may find ourselves designing drug-device symphonies rather than single-target interventions.
The human implications are profound. For patients with needle phobia, these microneedle patches offer a near-painless alternative. For populations in low-resource settings, they promise easier distribution of critical vaccines and medications without reliance on cold-chain infrastructure or highly trained staff. And for chronic conditions – like diabetes, autoimmune diseases, or even some cancers – they could provide more consistent and less invasive treatment over time.
The business implications are no less significant. PinPrint’s emergence as a dedicated therapeutics company, distinct from Carbon’s manufacturing focus, signals an understanding that technological innovation alone isn’t enough. It’s the integration of engineering with clinical insight, regulatory strategy, health system readiness, and patient acceptance that will ultimately decide whether these patches make it to market.
A template for future therapies
An intriguing idea is that lattice microneedles might eventually be adapted for real-time sensing. Imagine a single-use patch that not only delivers medication but also monitors biomarkers in the skin’s interstitial fluid, feeding data back to a physician or an AI-powered diagnostic system. This kind of closed-loop system – therapeutic and diagnostic in one – could one day redefine what it means to be “connected” to your own health.
Looking forward, the challenge may not be technological at all – but cultural. How do we retrain clinicians, rethink supply chains, and reframe patient expectations around this new category of therapeutics? As with any platform shift, the real disruption will be felt in the systems built around it.
What started as a sci-fi dream, an origin story Prof. DeSimone shared during his TED talk, has slowly morphed into reality. This story is about more than microneedles. It’s a window into how engineering can reshape the future of medicine. As researchers and clinicians grapple with the challenges of delivering fragile molecules to precise cellular targets, this approach – relying on modular, highly adaptable devices – may offer a template for future therapies.
Yet even as we look to the future, it’s clear that the present is already changing. The DeSimone Lab’s work challenges us to think beyond the patch itself: to consider how manufacturing, materials, and medicine can converge to create more humane, patient-centered tools. If successful, this vision could help close the gap between the promise of precision medicine and the realities of global health delivery.
The eWEAR-TCCI awards for science writing is a project commissioned by the Wearable Electronics Initiative (eWEAR) at Stanford University and made possible by funding through eWEAR industrial affiliates program benefactor Shanda Group and the Tianqiao and Chrissy Chen Institute (TCCI®).